Avelumab Immunotherapy: Management of Adverse Events Associated With New Treatment for Merkel Cell Carcinoma.
Aged
Antibodies, Monoclonal
/ adverse effects
Antibodies, Monoclonal, Humanized
Carcinoma, Merkel Cell
/ drug therapy
Drug-Related Side Effects and Adverse Reactions
/ etiology
Humans
Immunotherapy
/ adverse effects
Male
Middle Aged
Practice Guidelines as Topic
Skin Neoplasms
/ drug therapy
Treatment Outcome
United States
Merkel cell
adverse reactions
avelumab
carcinoma
drug-related side effects
Journal
Clinical journal of oncology nursing
ISSN: 1538-067X
Titre abrégé: Clin J Oncol Nurs
Pays: United States
ID NLM: 9705336
Informations de publication
Date de publication:
01 02 2019
01 02 2019
Historique:
entrez:
26
1
2019
pubmed:
27
1
2019
medline:
24
3
2020
Statut:
ppublish
Résumé
Metastatic Merkel cell carcinoma (mMCC) is a rare skin cancer with poor prognosis. Avelumab is the first approved treatment option for patients with mMCC. Immune checkpoint inhibitors, such as avelumab, are associated with unique toxicities that can be effectively addressed with prompt recognition and appropriate management. This article discusses the use of avelumab for the treatment of mMCC and management of associated toxicities. Literature on mMCC disease state and clinical trial data for avelumab were reviewed. Avelumab has been investigated in patients with mMCC either following disease progression after one or more prior lines of chemotherapy or no prior systemic therapy. These patients experience clinically meaningful benefit. About 70% of patients receiving avelumab experience treatment-related adverse events. Given the limited benefit of chemotherapy, managing symptoms related to avelumab is key to administering this effective treatment to patients with mMCC.
Sections du résumé
BACKGROUND
Metastatic Merkel cell carcinoma (mMCC) is a rare skin cancer with poor prognosis. Avelumab is the first approved treatment option for patients with mMCC. Immune checkpoint inhibitors, such as avelumab, are associated with unique toxicities that can be effectively addressed with prompt recognition and appropriate management.
OBJECTIVES
This article discusses the use of avelumab for the treatment of mMCC and management of associated toxicities.
METHODS
Literature on mMCC disease state and clinical trial data for avelumab were reviewed.
FINDINGS
Avelumab has been investigated in patients with mMCC either following disease progression after one or more prior lines of chemotherapy or no prior systemic therapy. These patients experience clinically meaningful benefit. About 70% of patients receiving avelumab experience treatment-related adverse events. Given the limited benefit of chemotherapy, managing symptoms related to avelumab is key to administering this effective treatment to patients with mMCC.
Identifiants
pubmed: 30682006
doi: 10.1188/19.CJON.E1-E9
doi:
Substances chimiques
Antibodies, Monoclonal
0
Antibodies, Monoclonal, Humanized
0
avelumab
KXG2PJ551I
Types de publication
Case Reports
Journal Article
Langues
eng